13D Filing: Avego Healthcare Capital, LLC and Acer Therapeutics Inc. (ACER)

Page 1 of 12

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Avego Healthcare Capital 527,983 527,983 8.18%
Mayura Trust B 527,983 527,983 8.18%
Bala Venkataraman 527,983 527,983 8.18%
Mayura One 527,983 527,983 8.18%
Yelena Epova 527,983 527,983 8.18%
Christopher R. Manning 527,983 527,983 8.18%

Page 1 of 12 – SEC Filing


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

ACER THERAPEUTICS INC.

(Name of Issuer)

common stock
(Title of Class of Securities)

00444P108
(CUSIP Number)

Thomas Vandervort
Avego Healthcare Capital LLC

1055B Powers Place
Alpharetta, GA 30009

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

September 19, 2017
(Date of Event which
Requires Filing of this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§240.13d -1(e), 240.13d -1(f) or 240.13d
-1(g), check the following box.[ ]

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See
§240.13d -7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

Follow Acer Therapeutics Inc. (NASDAQ:ACER)





























Page 1 of 12